Introducing a new cryoprecipitated coagulopathy treatment: INTERCEPT® Fibrinogen Complex
Presented at the Cerus Workshop at SABM Annual Meeting September 2021:
Clinical Need for, and Experience with, The New Pathogen Reduced Cryoprecipitated Fibrinogen Complex: INTERCEPT® Fibrinogen Complex
This presentation offers a brief product description of pathogen reduced cryoprecipitated fibrinogen complex, better known as INTERCEPT® Fibrinogen Complex, the first cryoprecipitated source of clotting factors ready for patients when minutes matter
Nadia Keltner, MSc, PhD
Associate Director, Therapeutics Market Development
Dr. Keltner is the Associate Director of the Therapeutics Market Development team for Cerus Corporation. Prior to the past 5 years at Cerus Corporation, she worked in physician and patient market research. She holds a BA from the University of California, Berkeley, an MSc from Columbia College of Physicians and Surgeons, and a PhD from Boston University School of Medicine.